Acyclovir bioavailability in patients with acute myelogenous leukemia treated with daunorubicin and cytarabine

Journal of Clinical Pharmacology

Volumn 48, Issue 8, 2008, Pages 995-998

  Sitar, Daniel S ^a,c   Aoki, Fred Y ^a   Bow, Eric J ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CANCERCARE MANITOBA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Acyclovir; Bioavailability; Cancer; Herpes simplex virus infection; Leukemia

Indexed keywords

ACICLOVIR; CYTARABINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MEGADOSE; HERPES SIMPLEX; HUMAN; MAXIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; SINGLE DRUG DOSE;

ACYCLOVIR; ADOLESCENT; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; CYTARABINE; DAUNORUBICIN; DRUG INTERACTIONS; FEMALE; HUMANS; INTESTINAL ABSORPTION; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED;

EID: 47549112677     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008319708     Document Type: Article

References (11)

1. Laskin OL Clinical pharmacokinetics of acyclovir. Clin Pharmacokinet. 1983 ; 8: 187-201.
2. Bow EJ, Kilpatrick MG, Scott BA, Clinch JJ, Cheang MS Acute myeloid leukemia in Manitoba: the consequences of standard "7+3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome. Cancer. 1994 ; 74: 52-60.
3. Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981 ; 58: 1203-1212.
4. Bow EJ, Meddings JB Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myelogenous leukemia. Leukemia. 2006 ; 20: 2087-2092.
5. Bras APM, Sitar DS, Aoki FY Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection. Can J Clin Pharmacol. 2001 ; 8: 207-211.
6. Gibaldi M., Perrier D. Pharmacokinetics. 2 nd ed. New York: Marcel Dekker ; 1982: 445-449.
7. Strauss SE, Smith HA, Brickman C., de Miranda P., McLaren C., Keeney RE Acyclovir for chronic mucocutaneous herpes simplex virus infection in immunosuppressed patients. Ann Intern Med. 1982 ; 96: 270-277.
8. De Miranda P., Whitley RJ, Blum MR, et al. Acyclovir kinetics after intravenous infusion. Clin Pharmacol Ther. 1979 ; 26: 718-728.
9. Wagstaff AJ, Faulds D., Goa K. Acyclovir: a reappraisal of its antiviral activity, pharmacokinetics and therapeutic efficacy. Drugs. 1994 ; 47: 153-205.
10. Blum MR, Liao SHT, De Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med. 1982 ; 73 (1A). 186-192.
11. Bow EJ, Loewen R., Cheang MS, Shore TB, Rubinger M., Schacter B. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol. 1997 ; 15: 2254-2261.